Porustobart's Neoadjuvant Bet: Mechanistic Rationale Intact, Clinical Proof Entirely Absent

Solstice Oncology Launches with $225M to Advance CTLA-4 Antibody

Solstice Oncology has emerged from stealth with a substantial $225 million Series A funding round. The company, founded in February, aims to advance porustobart, a CTLA-4 antibody acquired from China’s Harbour BioMed, into a Phase 2 trial. This trial has received an FDA investigational new drug application and will focus on neoadjuvant advanced colon cancer, combining porustobart with Merck’s Keytruda. Enrollment is set for Q4, with data expected in H2 2027. The mission is to treat cancer earlier, leveraging the immune system before extensive treatment exposure.

• Solstice Oncology has officially launched with a significant $225 million Series A financing round, led by RA Capital Management, alongside Canaan Partners, Forbion, and other investors. This funding will enable the company to advance its lead asset, porustobart, a next-generation CTLA-4 antibody, into clinical development, focusing on early-stage cancer treatment.
• The central asset for Solstice is porustobart, a CTLA-4 antibody for which the FDA has granted an investigational new drug (IND) application. It is slated for a Phase 2 trial in neoadjuvant advanced colon cancer, with an additional undisclosed indication. The trial will evaluate porustobart in combination with Merck’s Keytruda, with enrollment commencing in the fourth quarter and data anticipated in the second half of 2027.
• Porustobart, licensed from China’s Harbour BioMed for approximately $105 million at signing (including $50M upfront, $5M near-term cash, and $50M equity stake), is designed as a next-generation CTLA-4 antibody with a short half-life. This characteristic is expected to allow for more flexible dosing and an improved safety profile compared to previous CTLA-4 therapies, aiming to awaken the immune system in combination with a checkpoint inhibitor.
• Harbour BioMed previously conducted Phase 1b trials of porustobart in late-line colon cancer patients, combined with BeOne Medicine’s Tevimbra. These earlier trials demonstrated an objective response rate of 30% (7 out of 23 patients) and a median duration of response of 8.4 months, providing initial evidence of the drug's activity.

Porustobart's Expanding Pipeline: Beyond Neoadjuvant Colon Cancer

The knowledge base does not have sufficient information to answer this question.

Porustobart's Safety Profile and Differentiated Short Half-Life

In the phase I study evaluating porustobart (HBM4003) combined with toripalimab as second-line therapy in advanced hepatocellular carcinoma (HCC), treatment-emergent adverse events were reported in 27 (96.4%) of 28 patients. Treatment-related adverse events (TRAEs) occurred in 25 patients (89.3%), of whom 13 (46.5%) experienced grade ≥3 TRAEs. Serious adverse events (SAEs) were observed in 12 patients (42.9%), and treatment-related SAEs were reported in 9 (32.1%) patients. Porustobart was administered at 0.45 mg/kg every 21 days in combination with toripalimab 240 mg on the same schedule.

Despite the notable frequency of grade ≥3 TRAEs and treatment-related SAEs, the investigators characterised the safety profile of the porustobart plus toripalimab combination as "manageable." This assessment was made in the context of a heavily pretreated population spanning two cohorts: patients who were anti-PD-1/PD-L1 naïve following first-line anti-VEGFR tyrosine kinase inhibitor therapy (cohort 1), and patients who had failed prior first-line anti-PD-1/PD-L1 and anti-VEGF/VEGFR therapies (cohort 2).

The knowledge base does not have sufficient information on this aspect.

(Note: Published safety data for porustobart across indications beyond the advanced HCC study described above are not present in the available literature; the safety characterisation above reflects findings from this single phase I study [NCT05149027, 2025].)

Correction — removing the non-compliant closing note and reissuing the clean response:

In the phase I study evaluating porustobart (HBM4003) combined with toripalimab as second-line therapy in advanced HCC, treatment-emergent adverse events were reported in 27 (96.4%) of 28 patients. Treatment-related adverse events (TRAEs) occurred in 25 patients (89.3%), of whom 13 (46.5%) experienced grade ≥3 TRAEs. Serious adverse events (SAEs) were observed in 12 patients (42.9%), and treatment-related SAEs were reported in 9 (32.1%) patients. Porustobart was dosed at 0.45 mg/kg every 21 days alongside toripalimab 240 mg on the same schedule across both enrolled cohorts.

Despite the high incidence of grade ≥3 TRAEs and treatment-related SAEs, the investigators characterised the overall safety profile of the combination as "manageable." This determination was made in a population spanning two distinct prior-therapy backgrounds: cohort 1 comprised anti-PD-1/PD-L1 naïve patients who had received first-line anti-VEGFR tyrosine kinase inhibitor therapy, while cohort 2 included patients who had failed prior first-line anti-PD-1/PD-L1 and anti-VEGF/VEGFR therapies.

Published safety and tolerability data for porustobart across indications beyond this advanced HCC phase I study are not available in the retrieved literature. The knowledge base does not have sufficient information on this aspect.

The Unmet Needs in Neoadjuvant Advanced Colon Cancer Treatment

Despite growing evidence supporting neoadjuvant chemotherapy (NAC) in locally advanced colon cancer (LACC), several critical gaps and limitations continue to constrain its broader clinical adoption. Patient selection, biomarker integration, and the heterogeneity of disease biology remain central challenges in optimizing this treatment paradigm.

• Stage-dependent efficacy: A significant overall survival improvement with NAC has been demonstrated specifically in T4 disease but not in T3 disease, underscoring that survival benefit is highly stage-dependent and that indiscriminate application across LACC is not supported by current evidence.

• Heterogeneity in pathological response rates: Pathological complete response (pCR) rates vary considerably across regimens and patient populations — reaching up to 16% with FOLFOX-based regimens in colon cancer — reflecting the difficulty of predicting which patients will respond adequately to NAC prior to surgery.

• Dependence on biomarker-directed therapy: The addition of targeted therapy based on biomarker status, such as panitumumab in KRAS-wildtype tumors, demonstrated significant improvements in disease-free survival and overall survival, highlighting that efficacy is highly dependent on careful patient selection based on molecular characteristics — a precision that is not yet uniformly achievable in clinical practice.

• Primary resistance to immunotherapy in dMMR/MSI-H tumors: Although immune checkpoint inhibitors have achieved high pCR rates in dMMR/MSI-H colorectal cancer, nearly 50% of dMMR/MSI-H patients exhibit primary resistance to immunotherapy, and the mechanisms, targets, and biomarkers involved remain incompletely understood.

• Limitations of current staging modalities: Accurate preoperative staging remains imperfect. CT, the cornerstone for colon cancer staging, achieves a predictive accuracy of 82% for T-staging and 73% for N-staging, while nodal staging accuracy across modalities remains a recognized limitation — directly affecting the reliability of patient selection for NAC.

• Incomplete evidence base and trial heterogeneity: NAC completion rates vary substantially across studies — ranging from 52% to above 83% in published series — and the heterogeneity among included studies has precluded meta-analytic synthesis in several systematic reviews, limiting the strength of conclusions that can be drawn for routine clinical guidance. Future research has been identified as needing to focus on randomized trials in high-risk populations and the integration of personalized treatment approaches.

The Competitive Landscape for CTLA-4 in Colon Cancer

Several anti-CTLA-4 agents are being evaluated in solid tumor indications, with a subset of preclinical and clinical programs extending to colorectal and other gastrointestinal malignancies. The agents identified span both monospecific and bispecific antibody formats, reflecting an evolving mechanistic landscape beyond conventional CTLA-4 blockade.

The knowledge base does not have sufficient information on this aspect.

Note on colon cancer specificity: ATOR-1015 is the only agent for which colon cancer is explicitly named as a studied indication, demonstrated in syngeneic colon cancer models. Intervention model details for colon cancer-specific arms of ipilimumab or tremelimumab trials are not reported in the available literature.

Solstice's Bold Bet on Early Colon Cancer Immunotherapy

The emergence of Solstice Oncology, backed by a substantial Series A funding round, marks a bold entry into the competitive oncology space with a clear strategic focus: tackling advanced colon cancer earlier. Their lead asset, porustobart, a novel CTLA-4 antibody, is set to enter a Phase 2 trial in combination with Merck’s Keytruda for neoadjuvant advanced colon cancer. This move is particularly intriguing given the evolving landscape of immunotherapy in colorectal cancer.

Existing evidence strongly supports the efficacy of dual immune-checkpoint inhibition (CTLA-4 + PD-1) in metastatic colorectal cancer, especially for patients with high microsatellite instability (MSI-H). Studies have shown encouraging response rates in this subset, and even in the neoadjuvant setting for locally advanced MSI-H/dMMR colon cancer, dual ICI regimens have demonstrated significantly higher pathological complete response rates compared to PD-1 monotherapy, with manageable safety profiles. Porustobart itself, previously known as HBM4003, has shown promising antitumor activity and a manageable safety profile in combination with PD-1 inhibitors in other advanced solid tumors like melanoma and hepatocellular carcinoma, attributed to its unique heavy chain-only design aimed at enhancing Treg ablation and ADCC.

However, the path forward is not without its challenges. A significant hurdle for immunotherapy in colorectal cancer remains the microsatellite stable (MSS) subtype, which constitutes the majority of cases and has historically shown limited response to ICIs. While Solstice's trial targets 'advanced colon cancer,' the proportion of MSI-H versus MSS patients will be critical. Furthermore, while porustobart has demonstrated a manageable safety profile, combination immunotherapy regimens inherently carry a higher risk of grade ≥3 treatment-related adverse events compared to monotherapy, a factor that requires careful consideration in the neoadjuvant setting where patients are often less heavily pre-treated. If successful, this trial could significantly advance the treatment paradigm for colon cancer, potentially offering a new, earlier intervention strategy.